Rate and predictive parameters of novel Coronavirus 2019 (Sars-CoV-2) infections in a German General Practice

Ir J Med Sci. 2022 Feb;191(1):31-37. doi: 10.1007/s11845-021-02555-w. Epub 2021 Feb 16.

Abstract

Key points: In our clinical cross-sectional study, we identified 107 of 347 patients who were tested positive for antibodies of novel Coronavirus 2019 (SARS-CoV-2). Main symptoms were exhaustion and cough, exposition to other COVID-19-patients appeared frequently.

Background: There is urgent need for information on predictive parameters on immunity and infectivity in Coronavirus disease-2019 (COVID-19) pandemic. Our aim was to investigate distribution of novel Coronavirus 2019 (SARS-CoV-2) infections in a German General Practice and to learn about possible predictive parameters regarding infection and pathways of transmission.

Methods: In our cross-sectional study, we tested 347 patients of our General Practice using 2019-nCoV-2-IgG/IgM antibody test [2019-nCoV2 IgG/IgM Rapid Test Cassette (Ref.: INCP-402/INCP-402B; ACRO, BIOTECH, INC.)]. We asked for 13 specific symptoms and 4 questions to investigate patients' surroundings.

Results: A total of 107 of 347 patients were tested positive for antibodies (Immunoglobulin M-positive and/or Immunoglobulin G-positive). In antibody-positive group, body aches and rhinorrhea were seen more often and there were significantly less asymptomatic patients. Stay in area of risk was significantly more frequent in antibody-positive group as well as contact to infected persons. Distribution of other symptoms was not significantly different between both groups. Most adults or children with SARS-CoV-2 infection presented with mild flu-like symptoms.

Conclusion: A total of 30% of patients had antibodies. It was not possible to identify one solid predictive symptom. Serological testing may be helpful for the diagnosis of suspected patients with negative RT-PCR results and for the identification of asymptomatic infections.

Keywords: Antibodies; COVID-19; Exhaustion; Pandemic; SARS-CoV-2.

MeSH terms

  • Adult
  • Antibodies, Viral
  • COVID-19*
  • Child
  • Cross-Sectional Studies
  • Family Practice
  • Humans
  • Pandemics
  • SARS-CoV-2*
  • Sensitivity and Specificity

Substances

  • Antibodies, Viral